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reactions. This is further supported by
comparable studies in athymic (" nude ")
mice, where admixture with BCG prevented
subcutaneous development of rat tumour cell
inocula.
The implication from these findings is that
localized BCG treatment may still be applic-
able clinically, even when immunosuppression
has resulted from chemotherapy or radio-
therapy.
TUMOUR ANTIGEN IN HUMAN CAN-
CER PATIENTS' SERA. J. G. BOWEN,
Cancer Research Campaign Laboratories,
University of Nottingham.
Previous studies (Baldwin, Bowen and
Price, Br. J. Cancer, 1973, 28, 16) have
shown that tumour specific antigen can be
isolated from the serum of rats bearing a
transplanted aminoazo dye-induced hepa-
toma. The present study was undertaken to
determine if the sera of human bladder
cancer patients contained a tumour specific
antigen. Sera were fractionated by Sepha-
dex G-150 gel chromatography and material
with a molecular weight less than 150,000
Daltons examined for the presence of tumour
specific antigen by the leucocyte migration
inhibition test using leucocytes from bladder
cancer patients, other cancer patients and
non-cancer hospital patients. Antigen could
be detected in the sera of patients bearing
turnour in situ and those within one month of
tumour elimination. Patients tumour free
for longer than 3-4 years lacked reactivity
against the tumour bearer serum fraction.
CELL MEDIATED CYTOTOXICITY
(CMC) IN PATIENTS WITH ACUTE
MYELOBLASTIC LEUKAEMIA RE-
CEIVING IMMUNOTHERAPY. G. M.
TAYLOR, R. HARRIS and C. B. FREEMAN,
Department of Medical Genetics, St Mary's
Hospital, Manchester.
The effect of immunotherapy with allo-
geneic leukaemic blasts in patients with
acute myeloid leukaemia (AML) was assessed
by stimulating lymphocytes from these
patients when in remission and also lympho-
cytes from normal donors with immuno-
therapy blasts (I blasts), Burkitt's lymphoma
(RAJI) cells and normal lymphoblastoid
cells (LCL). After 6 days in culture,
stimulated lymphocytes were cross-tested for
cell mediated cytoxicity (CMC) against 51Cr
-labelled target cells of the same origin as
those used to stimulate the lymphocytes.
Patients on immunotherapy, and stimulated
invitrowithIblasts invariably showed ahigher
level of line directed CMC compared with
normals whereas cross tests of the same
lymphocytes against RAJI and LCL cells
revealed lower, though reproducible, cytoto-
xicity. RAJI generally failed to produce
cytotoxicity either in patients or normals,
whilst LCL induced cytotoxicity in both
sources oflymphocytes, withsome evidence of
cross-reactivity. Immunotherapy patients
seem topossessa pool oflymphocytes capable
of restimulation in vitro to give high levelsof
CMC,apropertywhichcouldbeusefulforevalu-
ating the response to immunotherapy ofAML
patients and which could aid the search for
tumour associated antigens on autochthonous
blasts. Moreover, CMC response is direct
evidence that the measures being used at
present to induce cell mediated immunity
in these patients do in fact work and may
be of value in selecting cells for use in
immunotherapy.
ACTIVE IMMUNOTHERAPY IN
ACUTE MYELOID LEUKAEMIA. C. B
FREEMAN, G. M. TAYLOR and R. HARRIS,
St Mary's Hospital, Manchester, and C. G.
GEARY, J. E. MACIVER and I. W. DELAMORE,
Manchester Royal Infirmary.
The duration of first remission in a small
group (7) of acute myeloid leukaemia (AML)
patients maintained with irradiated allo-
geneic leukaemia cells and BCG, after initial
consolidation chemotherapy, was similar to
that achieved in comparable trials using
conventional chemotherapy (Freeman et al.,
Br. med. J., 1973, iv, 571). In a second series
of 20 patients in the MRC 6th AML Trial, to
whom the same immunotherapy was given
but without prior consolidation chemo-
therapy, the median duration of first re-
mission was considerably shorter.
Compared with patients receiving other
therapeutic protocols, there was a remarkably
high reinduction rate following relapse in
both series of patients maintained with
immunotherapy alone (second remissions in
group 1: 5/6, group 2: 12/18 with four third
remissions) and the overall survival figures
are very encouraging (group 1: 4/7 alive,
current mean survival 115 weeks, group 2:
13/20, current mean survival 50 weeks).ABSTRACTS OF MEMBERS PAPERS 243
The high reinduction rate may result
from (1) avoidance of drug resistance, (2)
early diagnosis ofrelapse or (3) positive effect
of immunotherapy or a combination of these
factors.
IMMUNE COMPETENCE IN COLON
CANCER: RELATIONSHIP OF PRE-
TREATMENT TESTS TO DIAGNOSIS
AND TUMOUR STAGE. A. M. MANDER,
P. M. BOLTON, R. H. WHITEHEAD, R. G.
NEWCOMBE and L. E. HUGHES, Department
of Surgery, Welsh National School of Medi-
cine, Cardiff.
A spectrum of immunological tests was
performed to assess cellular and humoral
immunity in 40 patients with colon cancer.
Controls had suspected cancer but proved to
have benign disease.
The tests employed were measurements of
peripheralwhitecellcount, lymphocyte count,
serum immunoglobulin levels, lymphocyte
response to PHA, DNCB response, and the
Montoux test. Results were correlated with
diagnosis and tumour stage. The colon
cancer patients had both absolute and
relative lymphocytopaenia. Serum IgM and
IgA levels were significantly raised in the
cancer group and were highest in the patients
with distant spread. No difference in
lymphocyte response to PHA was observed.
DNCB and Mantoux responses were markedly
depressed in the cancer group even in patients
with early cancer. Discrimination between
benign and malignant conditions was not
greatly improved by using the tests in
combination.
HOST TUMOUR RELATIONSHIP IN
STOMACH CANCER-CORRELATION
OF HISTOLOGICAL CRITERIA WITH
TESTS OF IMMUNE COMPETENCE.
A. M. MANDER, C. A. MORGAN, E. W. OWEN,
J. ZLOSNICK and L. E. HUGHES, Welsh
National School of Medicine, Cardiff.
The current prospective study involves
multifactorial computer analysis of 50
stomach cancer patients who have been
assessed from two separate approaches: the
first by preoperative estimation of host
immune competence, measuring lymphocyte
response to phytohaemagglutinin, peripheral
lymphocyte count, serum immunoglobulin
levels, Mantoux response and dinitrochloro-
benzene skin testing, and the second approach
by histological examination of tumour and
lymph nodes for evidence of cellular and
humoral immune response.
Correlation of the two sets of data with
each other and with clinical tumour staging
has given a broad view of host tumour
interaction in stomach cancer. The results
will allow an assessment of whether histo-
logical parameters of cellular and humoral
immunity correlate with results obtained by
immunosurveillance tests, and which ofthese
is most relevant to the clinical outcome ofthe
disease.
HUMORAL IMMUNITY IN HUMAN
LUNG NEOPLASIA. M. DAWSON and
M. MOORE, Paterson Laboratories, Man-
chester.
Sera from patients with carcinoma of the
lung were examined for evidence of humoral
immunity towards allogeneic lung carcinoma
cells in short-term culture.
Microcytotoxicity assays were used to
investigate: (a) complement dependent cyto-
toxicity; (b) serum mediated cellular cyto-
toxicity and (c) " blocking" activity of sera
towards leucocytes obtained from patients
with lung carcinoma.
The incidence of complement dependent
cytotoxic antibody to the sera was low, only
3/18 (17%) sera giving positive reactions. A
higher proportion 8/18 (44%) of the same
sera were found toiinduce cellularcytotoxicity
against lung carcinoma cells in leucocytes
obtained from healthy donors, while " block-
ing" activity towards lung cancer patients'
leucocytes was found in 10/18 (56%) sera.
The latter phenomenon was not specific since
5/7 (71%) sera from patients with unrelated
cancers also reduced the cytotoxicity of
leucocytes from lung cancer patients for
cultured lung carcinoma cells. The impli-
cations ofthese findings for the interpretation
of in vitro cytotoxicity tests in the human
allogeneic context are to be examined.
MACROPHAGE MIGRATION INHIBI-
TION AND IMMUNOGLOBULIN PRO-
DUCTION BY HODGKIN'S DISEASE
(HD) BIOPSY SPECIMENS IN VITRO.
D. B. JONES, S. V. PAYNE, J. L. SMITH, and
D. H. WRIGHT, Department of Experimental
Pathology, Southampton University.